Revumenib w/ 7+3 cytarabine + daunorubicin

May 12, 2026 — Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX) announced that 12 abstracts on Revuforj® (revumenib), its oral first-in-class menin inhibitor, were released on the European Hematology Association (EHA) website ahead of the EHA 2026 Congress (June 11–14, 2026; Stockholm). The abstracts span revumenib use across the acute leukemia continuum and genetic subtypes (KMT2A-rearranged, NPM1-mutated, and NUP98-rearranged).

Highlighted presentations include: interim findings from the multicenter real-world ROAR study in relapsed/refractory (R/R) acute leukemia; updated Phase 1 frontline combination data with intensive chemotherapy in newly diagnosed AML; post–hematopoietic stem cell transplant (HSCT) maintenance outcomes (including an encore of ASCO 2026 data and a post hoc AUGMENT-101 analysis); updated SAVE trial data combining revumenib with venetoclax and decitabine/cedazuridine in R/R AML; and activity in R/R NUP98r acute leukemia (AUGMENT-101/expanded access).

Business/clinical significance: Syndax positions the breadth of accepted EHA data—particularly post-HSCT outcomes and combination response depth/MRD negativity—as supportive of ongoing pivotal trials and broader adoption in genetically defined AML populations.